Detection of N-ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation

Blood

Volumn 98, Issue 5, 2001, Pages 1555-1560

  Kalakonda, Nagesh ^a,b   Rothwell, Dominic G ^a,b   Howard Scarffe, J ^a,b   Norton, John D ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; K RAS PROTEIN; OLIGONUCLEOTIDE; PROTEIN BCL 6; RAS PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL COMPARTMENTALIZATION; CELL HETEROGENEITY; CELL POPULATION; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMUNOPHENOTYPING; MALE; MULTIPLE MYELOMA; ONCOGENE N RAS; ONCOGENE RAS; PLASMA CELL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN N RAS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; TUMOR CELL; UNTRANSLATED REGION;

EID: 0035469865     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1555     Document Type: Article

References (33)

1. Desikan KR, Dhodapkar MV, Munshi NC, Barlogie B. Recent advances in the treatment of multiple myeloma. Curr Opin Hematol. 1999;6:216-221.
2. Attal M, Harousseau JL, Stopppa AM, et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective randomised trial. N Engl J Med. 1996;335:91-97.
3. Anderson KC. Who benefits from high dose therapy for multiple myeloma? J Clin Oncol. 1995:13:1291-1296.
4. Ruiz-Arguelles GJ, San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clin Proc. 1994;69:684-690.
5. San-Miguel JF, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma; influence on the biology and clinical course of the disease. Br J Haematol. 1991;77:185-190.
6. Epstein J, Hoover R, Kornbluth J, Barlogie B. Biological aspects of multiple myeloma. Baillieres Clin Haematol. 1995;8:721-734.
7. Neri A, Murphy JP, Cro P, et al. Ras oncogene mutation in multiple myeloma. J Exp Med. 1989;170:1715-1725.
8. Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene. 1990;5:1659-1663.
9. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708-2713.
10. Corradini P, Ladetto M, Inghirami G, Boccadoro M, Pileri A. N-and K-ras oncogenes in plasma cell dyscrasias. Leuk Lymphoma. 1994;15:17-20.
11. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood. 1996;88:2699-2706.
12. Chesi M, Nardini E, Brents L, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260-264.
13. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457-4463.
14. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17:226-230.
15. Hallek M, Leif Bergsagel P, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
16. Corradini P, Inghirami G, Astolfi M, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia. 1994;8:758-767.
17. Berenson JR, Bergsagel PL, Munshi N. Initiation and maintenance of multiple myeloma. Semin Hematol. 1999;36:9-13.
18. Farr CJ, Saiki RK, Ehrlich HA, McCormick F, Marshall CJ. Analysis of ras gene mutations in acute myeloid leukaemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A. 1988;85:1629-1633.
19. Toksoz D, Farr CJ, Marshall CJ. Ras genes and acute myeloid leukaemia. Br J Haematol. 1989;71:1-6.
20. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera F. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A. 1988;85:9268-9272.
21. Browett PJ, Norton JD. Analysis of ras gene mutations and methylation state in human leukemias. Oncogene. 1989;4:1029-1036.
22. Jacobson DR, Mills NE. A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene. 1994;9:553-563.
23. Toksoz D, Farr CJ, Marshall CJ. Ras gene activation in a minor proportion of the blast population in acute myeloid leukemia. Oncogene. 1987;1:409-413.
24. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6:1353-1362.
25. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science. 1998;280:1750-1752.
26. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumours. Science. 1992;256:102-105.
27. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A. 1998;95:11816-11821.
28. Dalla-Favera R, Migliazza A, Chang CC, et al. Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immun. 1999;246:257-265.
29. Seremetis S, Inghirami G, Ferrero D, et al. Transformation and plasmacytoid differentiation of EBV infected human B lymphoblasts by ras oncogenes. Science. 1989;243:660-663.
30. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res. 1995;55:3640-3646.
31. Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.Cancer Res. 1997;57:2268-2275.
32. Nagesh K, Rothwell DG, Heighway J, et al. Subclones harbouring point mutations in codon 61 of the N-ras gene are universal at presentation in multiple myeloma [abstract]. Blood. 1998;92:1056a.
33. Rothwell DG, Kalakonda N, Scarffe JH, Norton JD, Chopra R. Tumour cell population dynamics in multiple myeloma-analysis of N-ras and BCL6 mutations [abstract]. Blood. 1999;94:2426a.